Advertisement

Advertisement

News

Phase II ZUMA-12 Trial Evaluates First-Line Use of Axicabtagene Ciloleucel in High-Risk LBCL

News

Predicting Remission With CAR T-Cell Therapy in Large B-Cell Lymphoma: Focus on FDG-PET Imaging

News

IMpower150 Mutational Subgroup Analysis of Chemoimmunotherapy for KRAS-Mutated Lung Cancer

News

Can Immune Checkpoint Inhibitors Improve Pathologic Complete Response in Breast Cancer?

News

AACR 2022: Phase II Trial of Pembrolizumab Combined With Oncolytic Vaccine in Bladder Cancer

News

AACR 2022: KEYNOTE-992 to Study Pembrolizumab Plus Chemoradiotherapy for Bladder Cancer

Medical Literature

Diversity in Macrophage Function Among LC3-Associated Phagocytosis of AML Bone Marrow

Tony Mok, MD, on Oncogene-Addicted NSCLC: Expert Perspective on the Challenges

Toni Choueiri, MD, on Newer Agents in the Treatment of Renal Cell Carcinoma

View More

Advertisement

JNCCN Spotlights

UPDATE Nivolumab and Ipilimumab in Renal Cell Carcinoma

(UPDATE) Daratumumab (MM)

View More

More

News

Can Addition of T-DM1 Improve Outcomes Over Standard Treatment in HER2-Positive Breast Cancer?

Use of Cabozantinib After Immunotherapy for Advanced Renal Cell Carcinoma

AACR 2022: Cemiplimab-rwlc in Treatment of Basal Cell Carcinoma After Hedgehog Inhibition

Targeting <em>HER2</em> Mutations in NSCLC With Triplet Therapy

Phase II INSPIRE Study: Can Chemoradiation Plus Durvalumab Improve Outcomes in Bladder Cancer?

AACR 2022: Phase II Trial of Pembrolizumab Combined With Oncolytic Vaccine in Bladder Cancer

5-Year PACIFIC Follow-Up: Durvalumab in Stage III NSCLC

Vaccine Plus Co-stimulated T Cells Under Study in Multiple Myeloma

View More

Advertisement

Published

Medical Literature

Daratumumab Combination Therapy for Relapsed or Refractory Multiple Myeloma

Ixazomib Plus Lenalidomide/Dexamethasone in Relapsed or Refractory Myeloma: China Continuation Study

Combination Treatment With or Without Transplantation in Multiple Myeloma

Impact of Subsidies on Use of Immunomodulatory Drugs in Medicare Beneficiaries With Myeloma

View More

Ongoing

CE Activities

Exploring the Current and Future Role of BCMA-Directed Therapy in the Management of Multiple Myeloma

Emerging Considerations in Triple-Negative Breast Cancer: Focus on Immunotherapy

Changing Treatment Landscape of Metastatic Head and Neck Squamous Cell Carcinoma With Anti–PD-1/PD-L1 Agents

Tumor Mutational Burden, Neoantigens, and a Pathway to Predicting Response to Checkpoint Inhibitors

View More

Available

Clinical Trials

Cancer Research Institute Immunotherapy Clinical Trials

Center for Immunotherapy Clinical Research Trials

Immunotherapy Clinical Trials at Fred Hutch Cancer Research Center

ClinicalTrials.gov Immunotherapy

View More

Resources

For Your Patients

ONS Immunotherapy News

ONS Immunotherapy Community

Society for Immunotherapy of Cancer Patient Resources

CancerCare on Immunotherapy

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2022 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.